QIBA CT Angiography Biomarker Committee (BC) Call

14 January 2019 at 11 AM CT Call Summary

On Call

Andrew Buckler, MS (Co-Chair) Kevin DeMarco, MD Svetlana Egorova, MD, PhD Laura Jimenez-Juan, MD Márton Kolossváry, PhD Kevin O'Donnell, MASc Taylor Richards, PhD Ehsan Samei, PhD Raquel Themudo, MD, PhD Marly van Assen, MSc Edwin J.R. van Beek, MD, PhD

RSNA Staff

Joe Koudelik Julie Lisiecki

Moderator: Andrew Buckler, MS

Profile Sections Discussed:

- All sections but claims have been written
- Claims will be discussed on the January 28th call
- Mr. Buckler reviewed changes that were made within the last month, including the following topics:
 - Executive Summary
 - o Formatted dose specification table with body mass index (BMI) measurements
 - Scanner protocols that would be used in QIBA conformance
 - Acquisition specifications common to arterial beds and coronary arteries
 - o Spatial resolution
- It was noted that the CT dose table for BMI is based on only one model from one manufacturer
 - It was suggested that a vendor-neutral dose table be constructed for reference based on the most common scanners
 - Drs. Samei and van Beek to collaborate off-line on designing such a table
- Discussion regarding noise levels and selection of parameters to achieve certain performance targets
 - While specification tables are necessary for individual vendors to demonstrate conformance, some specifications are kept more general in order to allow for vendor innovation
 - Mr. O'Donnell and Drs. van Beek and Samei to review assessment tables
- Dr. Taylor Richards also reviewed acquisition specifications common to arterial beds and coronary arteries
 Some compromises will need to be made regarding resolution vs. noise
- All were asked to review the placeholder text for the author section and make any necessary corrections to titles, degrees, etc.
- The updated Profile will be distributed to BC members who have participated on recent calls and will be posted to the <u>QIBA wiki</u> for review
- Comments in track change mode can be sent to Mr. Buckler by January 25th: <u>andrew.buckler@elucidbio.com</u>

Next calls:

• The group will begin working on the claims on the next call

Action items:

 All were asked to review the Profile (sent via separate email) and provide feedback to Mr. Buckler by Friday, January 25th: <u>andrew.buckler@elucidbio.com</u>

Next call: Monday, January 28th at 11 am CT